Citations

Showing 10 of 108094 citations.

Small Extracellular Vesicles Secreted by Nigrostriatal Astrocytes Rescue Cell Death and Preserve Mitochondrial Function in Parkinson's Disease
Leggio, Loredana , L’Episcopo, Francesca , Magrì, Andrea , Ulloa-Navas, María José , Paternò, Greta , Vivarelli, Silvia , Bastos, Carlos A. P. , Tirolo, Cataldo , Caniglia, Salvatore , Risiglione, Pierpaolo , Pappalardo, Fabrizio , Serra, Alessandro , García‐Tárraga, Patricia, Faria, Nuno, Powell, Jonathan J. , Peruzzotti‐Jametti, Luca , García‐Verdugo, José Manuel , Iraci, Nunzio , Testa, Nunzio , Caniglia, Salvatore , Risiglione, Pierpaolo , Pappalardo, Fabrizio , Serra, Alessandro , Peruzzotti-Jametti, Luca , Pluchino, Stefano , Messina, Angela , Marchetti, Bianca , Iraci, Nunzio , García-Verdugo, José M , García-Tárraga, Patricia

Mayo Clinic

Advanced Healthcare Materials | July 20, 2022 | Volume: 11 | Issue: 20 | Pages: No page available

10.1002/adhm.202201203 | PMID 35856921 Get It

Abstract Extracellular vesicles (EVs) are emerging as powerful players in cell‐to‐cell communication both in healthy and diseased brain. In Parkinson's disease (PD)—characterized by selective dopaminergic neuron death in ventral midbrain (VMB) and degeneration of their terminals in striatum (STR)—astrocytes exert dual harmful/protective functions, with mechanisms not fully elucidated. Here, this study shows that astrocytes from the VMB‐, STR‐, and VMB/STR‐depleted brains release a population of small EVs in a region‐specific manner. Interestingly, VMB‐astrocytes secreted the highest rate of EVs, which is further exclusively increased in response to CCL3, a chemokine that promotes robust dopaminergic neuroprotection in different PD models. The neuroprotective potential of nigrostriatal astrocyte‐EVs is investigated in differentiated versus undifferentiated SH‐SY5Y cells exposed to oxidative stress and mitochondrial toxicity. EVs from both VMB‐ and STR‐astrocytes counteract H 2 O 2 ‐induced caspase‐3 activation specifically in differentiated cells, with EVs from CCL3‐treated astrocytes showing a higher protective effect. High resolution respirometry further reveals that nigrostriatal astrocyte‐EVs rescue neuronal mitochondrial complex I function impaired by the neurotoxin MPP + . Notably, only EVs from VMB‐astrocyte fully restore ATP production, again specifically in differentiated SH‐SY5Y. These results highlight a regional diversity in the nigrostriatal system for the secretion and activities of astrocyte‐EVs, with neuroprotective implications for PD.
Incidence of Preclinical Heart Failure in a Community Population
Young, Kathleen A. , Scott, Christopher G. , Rodeheffer, Richard J. , Chen, Horng H. , Scott, Christopher

Mayo Clinic

Journal of the American Heart Association | July 20, 2022 | Volume: 11 | Issue: 15 | Pages: No page available

10.1161/jaha.122.025519 | PMID 35862175 Get It

Background A high prevalence of preclinical heart failure (HF) (Stages A and B) has previously been shown. The aim of this study was to explore factors associated with the incidence of preclinical HF in a community population. Methods and Results Retrospective review of 393 healthy community individuals aged ≥45 years from the Olmsted County Heart Function Study that returned for 2 visits, 4 years apart. At visit 2, individuals that remained normal were compared with those that developed preclinical HF. By the second visit, 191 (49%) developed preclinical HF (12.1 cases per 100 person‐years of follow‐up); 65 (34%) Stage A and 126 (66%) Stage B. Those that developed preclinical HF (n=191) were older ( P =0.004), had a higher body mass index ( P <0.001), and increased left ventricular mass index ( P =0.006). When evaluated separately, increased body mass index was seen with development of Stage A ( P <0.001) or Stage B ( P =0.009). Echocardiographic markers of diastolic function were statistically different in those that developed Stage A [higher E/e’ ( P <0.001), lower e’ ( P <0.001)] and Stage B [higher left atrial volume index ( P <0.001), higher E/e’ ( P <0.001), lower e’ ( P <0.001)]. NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) was higher at visit 2 in those that developed Stage A or B ( P <0.001 for both). Hypertension (57%), obesity (34%), and hyperlipidemia (25%) were common in the development of Stage A. Of patients who developed Stage B, 71% (n=84) had moderate or severe diastolic dysfunction. Conclusions There is a high incidence of preclinical HF in a community population. Development of Stage A was driven by hypertension and obesity, while preclinical diastolic dysfunction was seen commonly in those that developed Stage B.
Reply to: “The First Allogeneic Hematopoietic Stem Cell Transplantation in a Polish Patient with Adult‐Onset Leukoencephalopathy with Spheroids and Pigmented Glia”
Tipton, Philip W. , Wierenga, Klaas J. , Tipton, Philip W , Wszołek, Zbigniew K.

Mayo Clinic

Movement Disorders | July 20, 2022 | Volume: 37 | Issue: 7 | Pages: 1572-1573

10.1002/mds.29065 | PMID 35856729 Get It

Detecting Sources of Immune Activation and Viral Rebound in HIV Infection
Wietgrefe, Stephen W. , Duan, Lijie, Anderson, Jodi, Marqués, Guillermo , Sanders, Mark A , Cummins, Nathan W. , Karn, Jonathan , Pagliuzza, Amélie , Chomont, Nicolas , Sannier, Gérémy , Kaufmann, Daniel E. , Zuck, Paul, Howell, Bonnie J. , Reilly, Cavan , Herschhorn, Alon , Schacker, Timothy W. , Haase, Ashley T. , Cummins, Nathan W , Badley, Andrew D. , Dobrowolski, Curtis N. , Dubé, Mathieu , Wu, Guoxin

Mayo Clinic

Journal of Virology | July 20, 2022 | Volume: 96 | Issue: 15 | Pages: No page available

10.1128/jvi.00885-22 | PMID 35856674 Get It

Anti-retroviral therapy (ART) has greatly improved the quality and length of life for people living with HIV, but immune activation does not normalize during ART, and persistent immune activation has been linked to increased morbidity and mortality. We report a comparison of assays of two potential sources of immune activation during ART: rare cells producing HIV and the virus’ major viral protein, p24, benchmarked on a cell model of active and latent infections and a method to visualize HIV-producing cells.
Dynamic aphasia with emerging agrammatism, anomia, and aberrant frontal behaviors in a case of atypical parkinsonism
Chandregowda, Adithya , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R. , Machulda, Mary M.

Mayo Clinic

Neurology and Clinical Neuroscience | July 20, 2022 | Volume: 10 | Issue: 5 | Pages: 262-265

10.1111/ncn3.12658 | PMID 36386575 Get It

AbstractA 57‐year‐old man presented with dynamic aphasia with evolving agrammatism and anomia. Additionally, he exhibited emerging atypical parkinsonism and features of behavioral variant frontotemporal dementia. Insights pertinent to this complex clinical presentation are discussed.
Management of Empyema Thoracis
Odell, John A.

Mayo Clinic

Journal of the Royal Society of Medicine | July 20, 2022 | Volume: 87 | Issue: 8 | Pages: 466-470

10.1177/014107689408700814 | PMID 8071919 Get It

Vaginal Estrogen Therapy for the Genitourinary Symptoms of Menopause: Caution or Reassurance?
Cathcart-Rake, Elizabeth , Ruddy, Kathryn J. , Cathcart-Rake, Elizabeth J

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 20, 2022 | Volume: 114 | Issue: 10 | Pages: 1315-1316

10.1093/jnci/djac113 | PMID 35854417 Get It

Sleep and the Young Athlete
Coel, Rachel A. , Applewhite, Andres I. , Zaslow, Tracy , Cooper, George , Ton, Angie , Benjamin, Holly J. , Ton, Angie N, Pujalte, George G.A. , Cooper, George

Mayo Clinic

Sports Health: A Multidisciplinary Approach | July 20, 2022 | Volume: 15 | Issue: 4 | Pages: 537-546

10.1177/19417381221108732 | PMID 35855519 Get It

Context: Sleep plays a vital role in cognitive and physical performance. Teenage athletes (ages 13-19 years) are considered especially at risk for disordered sleep and associated negative cognitive, physical, and psychosomatic effects. However, there is a paucity of evidence-based recommendations to promote sleep quality and quantity in athletes who fall within this age range. We performed a review of the literature to reveal evidence-based findings and recommendations to help sports instructors, athletic trainers, physical therapists, physicians, and other team members caring for young athletes provide guidance on sleep optimization for peak sports performance and injury risk reduction. Methods: PubMed, Scopus, and Cochrane CENTRAL were searched on May 11, 2016, and then again on September 1, 2020, for relevant articles published to date. Study Design: Narrative review. Level of Evidence: Level 4. Results: Few studies exist on the effects disordered sleep may have on teenage athletes. By optimizing sleep patterns in young athletes during training and competitions, physical and mental performance, and overall well-being, may be optimized. Adequate sleep has been shown to improve the performance of athletes, although further studies are needed. Conclusion: Twenty-five percent of total sleep time should be deep sleep, with a recommended sleep time of 8 to 9 hours for most young athletes. Screen and television use during athletes’ bedtime should be minimized to improve sleep quality and quantity. For young athletes who travel, jet lag can be minimized by allowing 1 day per time zone crossed for adjustment, limiting caffeine intake, planning meals and onboard sleeping to coincide with destination schedules, timing arrivals in the morning whenever possible, and using noise-canceling headphones and eyeshades. Strength-of-Recommendation Taxonomy (SORT): B.
Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial
Pignolo, Robert J. , Keen, Richard , Wilson, Amy C. , Packman, Jeff, Strahs, Andrew, Grogan, Donna R., Baujat, Geneviève , Hsiao, Edward C. , Wilson, Amy, Kaplan, Frederick S.

Mayo Clinic

Journal of Bone and Mineral Research | July 20, 2022 | Volume: 37 | Issue: 10 | Pages: 1891-1902

10.1002/jbmr.4655 | PMID 35854638 Get It

ABSTRACT Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder characterized by progressive heterotopic ossification (HO), often heralded by flare-ups, leading to reduced movement and life expectancy. This placebo-controlled, double-blind trial (NCT02190747) evaluated palovarotene, an orally bioavailable selective retinoic acid receptor gamma agonist, for prevention of HO in patients with FOP. Patients experiencing a flare-up were enrolled in two cohorts: (1) patients ≥15 years were randomized 3:1 to palovarotene 10/5 mg (weeks 1–2/3–6) or placebo; (2) patients ≥6 years were randomized 3:3:2 to palovarotene 10/5 mg, palovarotene 5/2.5 mg (weeks 1–2/3–6), or placebo. Cohort data were pooled. The primary endpoint was the proportion of responders (no/minimal new HO at flare-up body region by plain radiograph) at week 6. Change from baseline in HO volume and new HO incidence were assessed by computed tomography (CT) at week 12. Tissue edema was assessed by magnetic resonance imaging (MRI) or ultrasound. Forty patients (aged 7–53 years) were enrolled (placebo: n = 10; palovarotene 5/2.5 mg: n = 9; palovarotene 10/5 mg: n = 21). Disease history was similar between groups. In the per-protocol population, the proportion of responders at week 6 by plain radiograph was 100% with palovarotene 10/5 mg; 88.9% with palovarotene 5/2.5 mg; 88.9% with placebo (Cochran-Armitage trend test: p = 0.17). At week 12, the proportions were 95.0% with palovarotene 10/5 mg; 88.9% with palovarotene 5/2.5 mg; 77.8% with placebo (Cochran-Armitage trend test: p = 0.15). Week 12 least-squares mean (LSmean) new HO volume, assessed by CT, was 3.8 × 103 mm3 with palovarotene 10/5 mg; 1.3 × 103 mm3 with palovarotene 5/2.5 mg; 18.0 × 103 mm3 with placebo (pairwise tests versus placebo: p ≤ 0.12). Palovarotene was well-tolerated. No patients discontinued treatment or required dose reduction; one patient had dose interruption due to elevated lipase. Although these findings were not statistically significant, they support further evaluation of palovarotene for prevention of HO in FOP in larger studies. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Applicants’ Perspectives on Virtual vs In-person Colorectal Residency Interviews
Jabri, Ali Al, D’Angelo, Anne-Lise D. , Kelley, Scott R. , D'Angelo, Jonathan D, D'Angelo, Anne-Lise D, Abelson, Jonathan S. , D’Angelo, Jonathan D. , Husain, Syed

Mayo Clinic

Diseases of the Colon & Rectum | July 19, 2022 | Volume: 65 | Issue: 10 | Pages: 1162-1166

10.1097/dcr.0000000000002545 | PMID 35853182 Get It